A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

Mise à jour : Il y a 4 ans
Référence : NCT00542386

Femme et Homme

Extrait

This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.


Critère d'inclusion

  • chronic kidney disease ,dialysis ,Hyperphosphatemia ,Dyslipidemia


Liens